BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18080025)

  • 1. [Ertapenem].
    Gobernado M; Acuña C
    Rev Esp Quimioter; 2007 Sep; 20(3):277-99. PubMed ID: 18080025
    [No Abstract]   [Full Text] [Related]  

  • 2. [Beta-lactam antibiotics].
    Suárez C; Gudiol F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):116-29. PubMed ID: 19254642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Lactam and glycopeptide antibiotics: first and last line of defense?
    Jovetic S; Zhu Y; Marcone GL; Marinelli F; Tramper J
    Trends Biotechnol; 2010 Dec; 28(12):596-604. PubMed ID: 20970210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
    Arguedas A; Cespedes J; Botet FA; Blumer J; Yogev R; Gesser R; Wang J; West J; Snyder T; Wimmer W;
    Int J Antimicrob Agents; 2009 Feb; 33(2):163-7. PubMed ID: 18945594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis: ertapenem for complicated intra-abdominal infections.
    Falagas ME; Peppas G; Makris GC; Karageorgopoulos DE; Matthaiou DK
    Aliment Pharmacol Ther; 2008 May; 27(10):919-31. PubMed ID: 18266994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Part II. Introduction to the beta-lactam antibiotics.
    Cooper TW; Gibbs WJ; Bronze MS; Greenfield RA
    J Okla State Med Assoc; 2006 Oct; 99(10):516-20. PubMed ID: 17125105
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Karamanis EM, Matthaiou DK, Moraitis LI, et al. Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials. Spine 2008;33:E297-E304.
    Kłuciński P; Ekiel A; Wilk I; Martirosian G
    Spine (Phila Pa 1976); 2009 Feb; 34(4):420; author reply 420-1. PubMed ID: 19214107
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
    Nix DE; Majumdar AK; DiNubile MJ
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii23-8. PubMed ID: 15150180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is monotherapy with β-lactam antibiotics still up to date? New aspects for treatment of severe infections].
    Heizmann P; Lode H; Heizmann WR
    Dtsch Med Wochenschr; 2012 Feb; 137(6):267-70. PubMed ID: 22294112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Part V. Other beta-lactam antimicrobials.
    Gibbs WJ; Cooper TW; Bronze MS; Greenfield RA
    J Okla State Med Assoc; 2007 Jan; 100(1):23-5. PubMed ID: 17378498
    [No Abstract]   [Full Text] [Related]  

  • 11. [A comment on the contribution by H. Rosin: "Beta-lactam antibiotics"].
    Cullmann W; Opferkuch W
    Internist (Berl); 1989 Sep; 30(9):628-9. PubMed ID: 2807787
    [No Abstract]   [Full Text] [Related]  

  • 12. Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients.
    Yellin AE; Johnson J; Higareda I; Congeni BL; Arrieta AC; Fernsler D; West J; Gesser R
    Am J Surg; 2007 Sep; 194(3):367-74. PubMed ID: 17693284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime.
    Bazan JA; Martin SI; Kaye KM
    Infect Dis Clin North Am; 2009 Dec; 23(4):983-96, ix. PubMed ID: 19909894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity.
    Fisher JF; Meroueh SO; Mobashery S
    Chem Rev; 2005 Feb; 105(2):395-424. PubMed ID: 15700950
    [No Abstract]   [Full Text] [Related]  

  • 15. [The beta-lactam antibiotics].
    Rosin H
    Internist (Berl); 1989 Jan; 30(1):2-12. PubMed ID: 2646236
    [No Abstract]   [Full Text] [Related]  

  • 16. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus.
    Elliott DJ; Zaoutis TE; Troxel AB; Loh A; Keren R
    Pediatrics; 2009 Jun; 123(6):e959-66. PubMed ID: 19470525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.
    Hadley JA; Tillotson GS; Tosiello R; Echols RM
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):923-37. PubMed ID: 17181408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactams with or without aminoglycosides.
    Alfandari S; Boussekey N
    Clin Infect Dis; 2005 Nov; 41(10):1542-3; author reply 1543-4. PubMed ID: 16231273
    [No Abstract]   [Full Text] [Related]  

  • 19. [Which partner for the betalactam agent in empirical combined therapy? II. Aminoglycoside].
    Mimoz O; Grollier G
    Ann Fr Anesth Reanim; 2004 Jun; 23(6):639-42. PubMed ID: 15234735
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bacampicillin].
    Mashimo K
    Jpn J Antibiot; 1982 Dec; 35(12):2723-35. PubMed ID: 6763634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.